Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Bull-like who wrote (403)	11/6/1998 7:01:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 642

Excerpt from a Bloomberg article on PFE's analyst meeting (it would be at least 2000 before the drug is approved by the FDA): Osteoporosis For its osteoporosis drug, Pfizer said it intends to conduct ''head-to-head'' comparisons with competing products. Eli Lilly & Co. makes a similar drug, Evista. Evista is the first of a class of drugs that appear to mimic estrogen's benefits without causing side effects. Lilly already is studying Evista for use in prevent breast cancer and heart disease. The drug is approved for use in osteoporosis, or a thinning of the bones that makes them more fragile. Pfizer said it has two likely compounds for its similar drug. It expects to put the better of these two into so-called Phase III trials next year. This is the last stage of testing needed to apply for U.S. Food and Drug Administration approval.

To: Bull-like who wrote (403)	11/9/1998 2:10:00 PM
From: Anthony Wong	Respond to of 642

RESEARCH ALERT-Eli Lilly target raised Monday November 9, 10:41 am Eastern Time CHICAGO, Nov 9 (Reuters) - Everen Securities said Monday that it raised its price target for drug maker Eli Lilly & Co. to $94 a share in the intermediate term from $88 a share based on new data concerning its anticlotting drug ReoPro. -- Indianapolis-based Lilly markets the blood clot buster in an agreement with manufacturer Centocor Inc. (Nasdaq:CNTO - news), a Malvern, Pa.-based biotechnology firm. -- Centocor on Monday presented a study showing ReoPro, when used in combination with stents -- small wire-mesh tubes used to prop open weak coronary blood vessels -- reduced risk of death by 57 percent in patients with heart disease. -- The study was presented at an American Heart Association conference. It compared patients with ischemic heart disease who used a combination of ReoPro with stents to reopen blocked coronary arteries to patients undergoing stenting alone. -- ''Our current 1999 (sales estimate) for ReoPro is $480 million with (the 2000 estimate) at $600 million. We expect these estimates to potentially increase,'' Everen said. -- Shares in Lilly were down 1-15/16 at 85-5/8 on the New York Stock Exchange, while shares in Centocor were up 3-1/16 at 50-5/16 on Nasdaq in early trading.